Moderna (NASDAQ:MRNA) confirms that it is in advanced discussions with the European Commission on an agreement to supply 80M doses of its COVID-19 vaccine, currently dubbed mRNA-1273. The deal will include the option to buy 80M additional doses.
It is scaling production aimed at delivering ~500M doses/year, with an upside of 1B doses annually, in 2021 (note that this is a run rate so the actual number of doses delivered next year will be less).
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.